Humacyte (NASDAQ:HUMA) Shares Up 5.8%

Humacyte, Inc. (NASDAQ:HUMA)’s stock price was up 5.8% during mid-day trading on Wednesday . The stock traded as high as $6.20 and last traded at $6.20. Approximately 329,129 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 1,821,085 shares. The stock had previously closed at $5.86.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Humacyte in a research report on Tuesday, July 2nd. Benchmark reissued a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Tuesday, July 2nd. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price target on shares of Humacyte in a research note on Tuesday, March 26th.

Humacyte Stock Performance

The firm has a market capitalization of $695.43 million, a P/E ratio of -5.84 and a beta of 1.51. The company has a debt-to-equity ratio of 0.61, a current ratio of 8.37 and a quick ratio of 8.37. The firm has a 50-day moving average price of $6.11 and a two-hundred day moving average price of $4.31.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Friday, May 10th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). On average, analysts forecast that Humacyte, Inc. will post -0.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Gordon M. Binder purchased 50,000 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were acquired at an average price of $6.78 per share, with a total value of $339,000.00. Following the transaction, the director now owns 160,000 shares of the company’s stock, valued at $1,084,800. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Humacyte news, Director Gordon M. Binder acquired 50,000 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was bought at an average cost of $6.78 per share, with a total value of $339,000.00. Following the completion of the purchase, the director now directly owns 160,000 shares in the company, valued at $1,084,800. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Laura E. Niklason sold 358,630 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $7.08, for a total transaction of $2,539,100.40. Following the transaction, the chief executive officer now directly owns 4,830,658 shares in the company, valued at approximately $34,201,058.64. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 54,412 shares of company stock worth $369,107 and have sold 1,628,820 shares worth $12,464,121. 23.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Whittier Trust Co. of Nevada Inc. bought a new stake in Humacyte during the fourth quarter valued at about $28,000. SG Americas Securities LLC grew its position in shares of Humacyte by 52.8% in the 4th quarter. SG Americas Securities LLC now owns 16,340 shares of the company’s stock worth $46,000 after buying an additional 5,645 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Humacyte by 350.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock worth $34,000 after acquiring an additional 9,325 shares in the last quarter. United Asset Strategies Inc. lifted its holdings in shares of Humacyte by 53.9% during the 4th quarter. United Asset Strategies Inc. now owns 221,308 shares of the company’s stock valued at $629,000 after purchasing an additional 77,500 shares during the last quarter. Finally, Powell Investment Advisors LLC grew its stake in shares of Humacyte by 75.0% during the fourth quarter. Powell Investment Advisors LLC now owns 21,000 shares of the company’s stock worth $60,000 after acquiring an additional 9,000 shares during the last quarter. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.